Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Arm A: Obinutuzumab in Combination With Chlorambucil	177
Overall Study	STARTED	Arm B: Acalabrutinib in Combination With Obinutuzumab	179
Overall Study	STARTED	Arm C: Acalabrutinib Monotherapy	179
Overall Study	Crossed Over From Arm A to Arm C	Arm A: Obinutuzumab in Combination With Chlorambucil	45
Overall Study	Crossed Over From Arm A to Arm C	Arm B: Acalabrutinib in Combination With Obinutuzumab	0
Overall Study	Crossed Over From Arm A to Arm C	Arm C: Acalabrutinib Monotherapy	0
Overall Study	COMPLETED	Arm A: Obinutuzumab in Combination With Chlorambucil	145
Overall Study	COMPLETED	Arm B: Acalabrutinib in Combination With Obinutuzumab	0
Overall Study	COMPLETED	Arm C: Acalabrutinib Monotherapy	0
Overall Study	NOT COMPLETED	Arm A: Obinutuzumab in Combination With Chlorambucil	32
Overall Study	NOT COMPLETED	Arm B: Acalabrutinib in Combination With Obinutuzumab	179
Overall Study	NOT COMPLETED	Arm C: Acalabrutinib Monotherapy	179

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02475681/flow